{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:09:45Z","timestamp":1794488985733,"version":"4.9.1"},"reference-count":213,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Cancer cells often encounter hypoxic and hypo-nutrient conditions, which force them to make adaptive changes to meet their high demands for energy and various biomaterials for biomass synthesis. As a result, enhanced catabolism (breakdown of macromolecules for energy production) and anabolism (macromolecule synthesis from bio-precursors) are induced in cancer. This phenomenon is called \u201cmetabolic reprogramming,\u201d a cancer hallmark contributing to cancer development, metastasis, and drug resistance. HCC and cholangiocarcinoma (CCA) are 2 different liver cancers with high intertumoral heterogeneity in terms of etiologies, mutational landscapes, transcriptomes, and histological representations. In agreement, metabolism in HCC or CCA is remarkably heterogeneous, although changes in the glycolytic pathways and an increase in the generation of lactate (the Warburg effect) have been frequently detected in those tumors. For example, HCC tumors with activated \u03b2-catenin are addicted to fatty acid catabolism, whereas HCC tumors derived from fatty liver avoid using fatty acids. In this review, we describe common metabolic alterations in HCC and CCA as well as metabolic features unique for their subsets. We discuss metabolism of NAFLD as well, because NAFLD will likely become a leading etiology of liver cancer in the coming years due to the obesity epidemic in the Western world. Furthermore, we outline the clinical implication of liver cancer metabolism and highlight the computation and systems biology approaches, such as genome-wide metabolic models, as a valuable tool allowing us to identify therapeutic targets and develop personalized treatments for liver cancer patients.<\/jats:p>","DOI":"10.1097\/hep.0000000000000005","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T16:00:26Z","timestamp":1681488026000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":115,"title":["Metabolic reprogramming and its clinical implication for liver cancer"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3934-7437","authenticated-orcid":false,"given":"Flora","family":"Yang","sequence":"first","affiliation":[{"name":"BA\/MD Joint Admission Scholars Program, University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7052-6513","authenticated-orcid":false,"given":"Leena","family":"Hilakivi-Clarke","sequence":"additional","affiliation":[{"name":"Food Science and Nutrition Section, The Hormel Institute, University of Minnesota, Austin, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-903X","authenticated-orcid":false,"given":"Aurpita","family":"Shaha","sequence":"additional","affiliation":[{"name":"Tumor Microenvironment and Metastasis Section, the Hormel Institute, University of Minnesota, Austin, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-9908","authenticated-orcid":false,"given":"Yuanguo","family":"Wang","sequence":"additional","affiliation":[{"name":"Tumor Microenvironment and Metastasis Section, the Hormel Institute, University of Minnesota, Austin, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-0514","authenticated-orcid":false,"given":"Xianghu","family":"Wang","sequence":"additional","affiliation":[{"name":"Tumor Microenvironment and Metastasis Section, the Hormel Institute, University of Minnesota, Austin, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5711-3565","authenticated-orcid":false,"given":"Yibin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Urology, Masonic Cancer Center, The University of Minnesota Medical School, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-5096","authenticated-orcid":false,"given":"Jinping","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-7976","authenticated-orcid":false,"given":"Ningling","family":"Kang","sequence":"additional","affiliation":[{"name":"Tumor Microenvironment and Metastasis Section, the Hormel Institute, University of Minnesota, Austin, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"R1-20251030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","article-title":"Mechanisms and implications of metabolic heterogeneity in cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Cell Metab"},{"key":"R2-20251030","doi-asserted-by":"crossref","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci Adv"},{"key":"R3-20251030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward","volume":"21","author":"Martinez-Reyes","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"R4-20251030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R5-20251030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"R6-20251030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"R7-20251030","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1042\/BST20160094","article-title":"The Warburg effect: 80 years on","volume":"44","author":"Potter","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"R8-20251030","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"R9-20251030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","article-title":"Metabolic reprogramming: the emerging concept and associated therapeutic strategies","volume":"34","author":"Yoshida","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"R10-20251030","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1111\/febs.13402","article-title":"Metabolic reprogramming of the tumour microenvironment","volume":"282","author":"Xing","year":"2015","journal-title":"FEBS J"},{"key":"R11-20251030","doi-asserted-by":"crossref","first-page":"6075403","DOI":"10.1155\/2018\/6075403","article-title":"Metabolic reprogramming of cancer associated fibroblasts: the slavery of stromal fibroblasts","volume":"2018","author":"Avagliano","year":"2018","journal-title":"Biomed Res Int"},{"key":"R12-20251030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41577-020-0406-2","article-title":"Lactate modulation of immune responses in inflammatory versus tumour microenvironments","volume":"21","author":"Certo","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"R13-20251030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fonc.2018.00081","article-title":"Metabolic symbiosis and immunomodulation: how tumor cell-derived lactate may disturb innate and adaptive immune responses","volume":"8","author":"Morrot","year":"2018","journal-title":"Front Oncol"},{"key":"R14-20251030","doi-asserted-by":"crossref","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"R15-20251030","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","article-title":"Metabolic rearrangements in primary liver cancers: cause and consequences","volume":"16","author":"Satriano","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R16-20251030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molmed.2018.02.006","article-title":"Genomic profiling and metabolic homeostasis in primary liver cancers","volume":"24","author":"Gingold","year":"2018","journal-title":"Trends Mol Med"},{"key":"R17-20251030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.29789","article-title":"cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation","volume":"68","author":"Brunt","year":"2018","journal-title":"Hepatology"},{"key":"R18-20251030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R19-20251030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0034-1394144","article-title":"Cholangiocarcinoma: molecular pathways and therapeutic opportunities","volume":"34","author":"Rizvi","year":"2014","journal-title":"Semin Liver Dis"},{"key":"R20-20251030","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.3748\/wjg.v22.i45.9933","article-title":"Reprogramming of glucose metabolism in hepatocellular carcinoma: progress and prospects","volume":"22","author":"Shang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R21-20251030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmed.2020.00113","article-title":"Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma","volume":"7","author":"Pant","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R22-20251030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1568009618666180430144441","article-title":"Glycolysis inhibition as a strategy for hepatocellular carcinoma treatment?","volume":"19","author":"Alves","year":"2019","journal-title":"Curr Cancer Drug Targets"},{"key":"R23-20251030","doi-asserted-by":"crossref","first-page":"591342","DOI":"10.3389\/fonc.2020.591342","article-title":"Metabolic reprogramming induces immune cell dysfunction in the tumor microenvironment of multiple myeloma","volume":"10","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"R24-20251030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/imm.12777","article-title":"Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes","volume":"152","author":"Allison","year":"2017","journal-title":"Immunology"},{"key":"R25-20251030","doi-asserted-by":"crossref","first-page":"8605471","DOI":"10.1155\/2018\/8605471","article-title":"Regulation of immune cell functions by metabolic reprogramming","volume":"2018","author":"Kim","year":"2018","journal-title":"J Immunol Res"},{"key":"R26-20251030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.immuni.2015.09.001","article-title":"Metabolic reprogramming of immune cells in cancer progression","volume":"43","author":"Biswas","year":"2015","journal-title":"Immunity"},{"key":"R27-20251030","first-page":"55","article-title":"Glycolysis as the central core of fermentation","volume":"156","author":"Taillefer","year":"2016","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"R28-20251030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","article-title":"The emerging role and targetability of the TCA cycle in cancer metabolism","volume":"9","author":"Anderson","year":"2018","journal-title":"Protein Cell"},{"key":"R29-20251030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-94-007-2869-1_1","article-title":"The oxidative phosphorylation system in mammalian mitochondria","volume":"942","author":"Papa","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"R30-20251030","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.3390\/ijms21113820","article-title":"Mitochondrial OXPHOS biogenesis: co-regulation of protein synthesis, import, and assembly pathways","volume":"21","author":"Tang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R31-20251030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","article-title":"The pentose phosphate pathway and cancer","volume":"39","author":"Patra","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"R32-20251030","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s13238-014-0082-8","article-title":"Regulation of the pentose phosphate pathway in cancer","volume":"5","author":"Jiang","year":"2014","journal-title":"Protein Cell"},{"key":"R33-20251030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/metabo10070285","article-title":"The pentose phosphate pathway dynamics in cancer and its dependency on intracellular pH","volume":"10","author":"Alfarouk","year":"2020","journal-title":"Metabolites"},{"key":"R34-20251030","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1242\/jcs.181016","article-title":"Cancer metabolism at a glance","volume":"129","author":"Vazquez","year":"2016","journal-title":"J Cell Sci"},{"key":"R35-20251030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","article-title":"Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression","volume":"73","author":"Li","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"R36-20251030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tibs.2014.02.004","article-title":"Serine and glycine metabolism in cancer","volume":"39","author":"Amelio","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"R37-20251030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cmet.2014.12.003","article-title":"Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA","volume":"21","author":"Tan","year":"2015","journal-title":"Cell Metab"},{"key":"R38-20251030","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1073\/pnas.1003428107","article-title":"Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity","volume":"107","author":"Weinberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R39-20251030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-4598-1-9","article-title":"Mitochondrial defects in cancer","volume":"1","author":"Carew","year":"2002","journal-title":"Mol Cancer"},{"key":"R40-20251030","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1196\/annals.1297.043","article-title":"Mitochondrial dysfunction is a common phenotype in aging and cancer","volume":"1019","author":"Singh","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R41-20251030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrg1606","article-title":"Mitochondrial DNA mutations in human disease","volume":"6","author":"Taylor","year":"2005","journal-title":"Nat Rev Genet"},{"key":"R42-20251030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R43-20251030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.999.65.3","article-title":"Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death","volume":"65","author":"Blum","year":"2005","journal-title":"Cancer Res"},{"key":"R44-20251030","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells","volume":"10","author":"Gottschalk","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R45-20251030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R46-20251030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"p53 in survival, death and metabolic health: a lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R47-20251030","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/0008-5472.CAN-03-0846","article-title":"The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression","volume":"64","author":"Schwartzenberg-Bar-Yoseph","year":"2004","journal-title":"Cancer Res"},{"key":"R48-20251030","first-page":"257","article-title":"Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer","volume":"51","author":"Coy","year":"2005","journal-title":"Clin Lab"},{"key":"R49-20251030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/321282","article-title":"Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma","volume":"69","author":"Astuti","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R50-20251030","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of Krebs cycle intermediates and over-expression of HIF1\u03b1 in tumours which result from germline FH and SDH mutations","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R51-20251030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"key":"R52-20251030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2350-9-20","article-title":"The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency","volume":"9","author":"Bayley","year":"2008","journal-title":"BMC Med Genet"},{"key":"R53-20251030","first-page":"4213","article-title":"Crucial role of the pentose phosphate pathway in malignant tumors","volume":"17","author":"Jin","year":"2019","journal-title":"Oncol Lett"},{"key":"R54-20251030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.seminoncol.2017.10.004","article-title":"Metabolic coupling and the Reverse Warburg Effect in cancer: implications for novel biomarker and anticancer agent development","volume":"44","author":"Wilde","year":"2017","journal-title":"Semin Oncol"},{"key":"R55-20251030","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"key":"R56-20251030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"R57-20251030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.bbrc.2018.11.182","article-title":"Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance","volume":"508","author":"Sun","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"R58-20251030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q\u2019s next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"key":"R59-20251030","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.cell.2013.04.023","article-title":"The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4","volume":"153","author":"Csibi","year":"2013","journal-title":"Cell"},{"key":"R60-20251030","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-09-0889","article-title":"MYC-induced cancer cell energy metabolism and therapeutic opportunities","volume":"15","author":"Dang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R61-20251030","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res"},{"key":"R62-20251030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1756-9966-30-58","article-title":"Oncogene addiction in gliomas: implications for molecular targeted therapy","volume":"30","author":"Yan","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"R63-20251030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R64-20251030","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1158\/1541-7786.MCR-14-0542","article-title":"Membrane-to-nucleus signals and epigenetic mechanisms for myofibroblastic activation and desmoplastic stroma: potential therapeutic targets for liver metastasis?","volume":"13","author":"Kang","year":"2015","journal-title":"Mol Cancer Res"},{"key":"R65-20251030","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.4161\/cc.21384","article-title":"Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: connecting TGF-beta signaling with \u201cWarburg-like\u201d cancer metabolism and L-lactate production","volume":"11","author":"Guido","year":"2012","journal-title":"Cell Cycle"},{"key":"R66-20251030","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.4161\/cc.10.15.16585","article-title":"Cancer cells metabolically \u201cfertilize\u201d the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors","volume":"10","author":"Martinez-Outschoorn","year":"2011","journal-title":"Cell Cycle"},{"key":"R67-20251030","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/0008-5472.CAN-12-1949","article-title":"Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay","volume":"72","author":"Fiaschi","year":"2012","journal-title":"Cancer Res"},{"key":"R68-20251030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","article-title":"Hepatocellular carcinoma: etiology and current and future drugs","volume":"9","author":"Jindal","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"R69-20251030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"R70-20251030","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"R71-20251030","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.28487","article-title":"Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype","volume":"63","author":"Matter","year":"2016","journal-title":"Hepatology"},{"key":"R72-20251030","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/1078-0432.CCR-14-0122","article-title":"Intratumor heterogeneity in hepatocellular carcinoma","volume":"21","author":"Friemel","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R73-20251030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcmgh.2017.05.004","article-title":"Identification of the consistently altered metabolic targets in human hepatocellular carcinoma","volume":"4","author":"Nwosu","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R74-20251030","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1158\/0008-5472.CAN-13-0308","article-title":"Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"R75-20251030","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R76-20251030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3892\/ijo.2020.5152","article-title":"Critical role of mTOR in regulating aerobic glycolysis in carcinogenesis (Review)","volume":"58","author":"Fan","year":"2021","journal-title":"Int J Oncol"},{"key":"R77-20251030","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2353\/ajpath.2009.080596","article-title":"GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis","volume":"174","author":"Amann","year":"2009","journal-title":"Am J Pathol"},{"key":"R78-20251030","doi-asserted-by":"crossref","first-page":"e0168907","DOI":"10.1371\/journal.pone.0168907","article-title":"GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"R79-20251030","first-page":"1047","article-title":"Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma","volume":"33","author":"Paudyal","year":"2008","journal-title":"Int J Oncol"},{"key":"R80-20251030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-017-02733-4","article-title":"Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin","volume":"9","author":"DeWaal","year":"2018","journal-title":"Nat Commun"},{"key":"R81-20251030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10620-014-3364-3","article-title":"Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma","volume":"60","author":"Guzman","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R82-20251030","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/jcp.27074","article-title":"Caveolin enhances hepatocellular carcinoma cell metabolism, migration, and invasion in vitro via a hexokinase 2-dependent mechanism","volume":"234","author":"Chai","year":"2019","journal-title":"J Cell Physiol"},{"key":"R83-20251030","first-page":"2538","article-title":"Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"R84-20251030","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1038\/onc.2014.325","article-title":"TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma","volume":"34","author":"Chen","year":"2015","journal-title":"Oncogene"},{"key":"R85-20251030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1101\/gad.278549.116","article-title":"Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma","volume":"30","author":"Dayton","year":"2016","journal-title":"Genes Dev"},{"key":"R86-20251030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1499-3872(15)60353-8","article-title":"Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma","volume":"14","author":"Wang","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R87-20251030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-2407-14-110","article-title":"The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management","volume":"14","author":"Faloppi","year":"2014","journal-title":"BMC Cancer"},{"key":"R88-20251030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/abbs\/gmy009","article-title":"Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition","volume":"50","author":"Lu","year":"2018","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"R89-20251030","doi-asserted-by":"crossref","first-page":"32375","DOI":"10.18632\/oncotarget.8632","article-title":"Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis","volume":"7","author":"Kowalik","year":"2016","journal-title":"Oncotarget"},{"key":"R90-20251030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13046-017-0637-7","article-title":"ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway","volume":"36","author":"Yin","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"R91-20251030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12032-011-9912-1","article-title":"O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation","volume":"29","author":"Zhu","year":"2012","journal-title":"Med Oncol"},{"key":"R92-20251030","doi-asserted-by":"crossref","first-page":"43842","DOI":"10.1038\/srep43842","article-title":"High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation","volume":"7","author":"Phoomak","year":"2017","journal-title":"Sci Rep"},{"key":"R93-20251030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3892\/or.2013.2886","article-title":"Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer","volume":"31","author":"Izuishi","year":"2014","journal-title":"Oncol Rep"},{"key":"R94-20251030","first-page":"1469","article-title":"Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy","volume":"18","author":"Paudyal","year":"2007","journal-title":"Oncol Rep"},{"key":"R95-20251030","first-page":"20210008","article-title":"Impact of (18)F-FDG-PET\/CT on clinical management in patients with cholangiocellular carcinoma","volume":"3","author":"Kiefer","year":"2021","journal-title":"BJR Open"},{"key":"R96-20251030","doi-asserted-by":"crossref","first-page":"e26015","DOI":"10.1097\/MD.0000000000026015","article-title":"Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: a STROBE study","volume":"100","author":"Hwang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R97-20251030","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.humpath.2014.03.008","article-title":"Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma","volume":"45","author":"Kubo","year":"2014","journal-title":"Hum Pathol"},{"key":"R98-20251030","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.dld.2015.03.017","article-title":"Relationship between 18-F-fluoro-deoxy-D-glucose uptake and expression of glucose transporter 1 and pyruvate kinase M2 in intrahepatic cholangiocarcinoma","volume":"47","author":"Suzuki","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R99-20251030","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jhep.2011.03.025","article-title":"Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway","volume":"55","author":"Kudo","year":"2011","journal-title":"J Hepatol"},{"key":"R100-20251030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2017.01.139","article-title":"Targeting hexokinase II as a possible therapy for cholangiocarcinoma","volume":"484","author":"Thamrongwaranggoon","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"R101-20251030","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cncr.27611","article-title":"Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer","volume":"119","author":"Dhar","year":"2013","journal-title":"Cancer"},{"key":"R102-20251030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-015-0462-6","article-title":"PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma","volume":"14","author":"Yu","year":"2015","journal-title":"Mol Cancer"},{"key":"R103-20251030","doi-asserted-by":"crossref","first-page":"24136","DOI":"10.1038\/srep24136","article-title":"The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy","volume":"6","author":"Faloppi","year":"2016","journal-title":"Sci Rep"},{"key":"R104-20251030","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.28496","article-title":"FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling","volume":"63","author":"Guan","year":"2016","journal-title":"Hepatology"},{"key":"R105-20251030","doi-asserted-by":"crossref","first-page":"e0173712","DOI":"10.1371\/journal.pone.0173712","article-title":"Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS","volume":"12","author":"Qu","year":"2017","journal-title":"PLoS One"},{"issue":"suppl","key":"R106-20251030","first-page":"101","article-title":"Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma","volume":"13","author":"Phoomak","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"R107-20251030","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1053\/j.gastro.2013.01.054","article-title":"Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes","volume":"144","author":"Budhu","year":"2013","journal-title":"Gastroenterology"},{"key":"R108-20251030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/07853890310018458","article-title":"The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase","volume":"35","author":"Pollard","year":"2003","journal-title":"Ann Med"},{"key":"R109-20251030","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/s41598-018-21361-6","article-title":"Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect","volume":"8","author":"Tseng","year":"2018","journal-title":"Sci Rep"},{"key":"R110-20251030","doi-asserted-by":"crossref","first-page":"16294","DOI":"10.1038\/srep16294","article-title":"Comprehensive analysis of transcriptome and metabolome analysis in intrahepatic cholangiocarcinoma and hepatocellular carcinoma","volume":"5","author":"Murakami","year":"2015","journal-title":"Sci Rep"},{"key":"R111-20251030","first-page":"5275","article-title":"Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma","volume":"17","author":"Sanmai","year":"2019","journal-title":"Oncol Lett"},{"key":"R112-20251030","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/cam4.2089","article-title":"SIRT3 elicited an anti-Warburg effect through HIF1alpha\/PDK1\/PDHA1 to inhibit cholangiocarcinoma tumorigenesis","volume":"8","author":"Xu","year":"2019","journal-title":"Cancer Med"},{"key":"R113-20251030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatology"},{"key":"R114-20251030","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct idh-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"R115-20251030","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"R116-20251030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"R117-20251030","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist"},{"key":"R118-20251030","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","article-title":"Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets","volume":"21","author":"Zhu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R119-20251030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/gutjnl-2017-315448","article-title":"Beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids","volume":"68","author":"Senni","year":"2019","journal-title":"Gut"},{"key":"R120-20251030","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/gutjnl-2017-315193","article-title":"CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity","volume":"67","author":"Fujiwara","year":"2018","journal-title":"Gut"},{"key":"R121-20251030","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.2147\/OTT.S163266","article-title":"Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma","volume":"11","author":"Lin","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R122-20251030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/15592294.2018.1514239","article-title":"Histone variant macroH2A1 rewires carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells","volume":"13","author":"Lo","year":"2018","journal-title":"Epigenetics"},{"key":"R123-20251030","doi-asserted-by":"crossref","first-page":"29255","DOI":"10.18632\/oncotarget.8711","article-title":"SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1alpha-mediated mitochondrial biogenesis","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"R124-20251030","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.3390\/ijms22115543","article-title":"Epithelial-mesenchymal transition (EMT) Induced by TGF-beta in hepatocellular carcinoma cells reprograms lipid metabolism","volume":"22","author":"Soukupova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R125-20251030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-018-0494-0","article-title":"PGC1alpha promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect","volume":"9","author":"Dan","year":"2018","journal-title":"Cell Death Dis"},{"key":"R126-20251030","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jhep.2020.12.031","article-title":"Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma","volume":"74","author":"Raggi","year":"2021","journal-title":"J Hepatol"},{"key":"R127-20251030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/cancers10110447","article-title":"Lipid metabolic reprogramming in hepatocellular carcinoma","volume":"10","author":"Nakagawa","year":"2018","journal-title":"Cancers (Basel)"},{"key":"R128-20251030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hep.29184","article-title":"Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction","volume":"66","author":"Tohme","year":"2017","journal-title":"Hepatology"},{"key":"R129-20251030","first-page":"1010428317695031","article-title":"Peroxisome proliferator-activated receptor gamma coactivator-1 alpha acts as a tumor suppressor in hepatocellular carcinoma","volume":"39","author":"Liu","year":"2017","journal-title":"Tumour Biol"},{"key":"R130-20251030","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.celrep.2014.08.028","article-title":"HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression","volume":"8","author":"Huang","year":"2014","journal-title":"Cell Rep"},{"key":"R131-20251030","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.celrep.2015.10.045","article-title":"Stratification of hepatocellular carcinoma patients based on acetate utilization","volume":"13","author":"Bjornson","year":"2015","journal-title":"Cell Rep"},{"key":"R132-20251030","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/hep.28415","article-title":"Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients","volume":"63","author":"Wang","year":"2016","journal-title":"Hepatology"},{"key":"R133-20251030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1053\/j.gastro.2010.12.006","article-title":"Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma","volume":"140","author":"Calvisi","year":"2011","journal-title":"Gastroenterology"},{"key":"R134-20251030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1053\/j.gastro.2017.01.021","article-title":"Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6","volume":"152","author":"Lai","year":"2017","journal-title":"Gastroenterology"},{"key":"R135-20251030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jhep.2008.07.036","article-title":"Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma","volume":"50","author":"Yamashita","year":"2009","journal-title":"J Hepatol"},{"key":"R136-20251030","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/hep.28508","article-title":"Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans","volume":"63","author":"Li","year":"2016","journal-title":"Hepatology"},{"key":"R137-20251030","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/hep.32344","article-title":"Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids","volume":"76","author":"Ruiz de Gauna","year":"2022","journal-title":"Hepatology"},{"key":"R138-20251030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40170-021-00266-5","article-title":"Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma","volume":"9","author":"Padthaisong","year":"2021","journal-title":"Cancer Metab"},{"key":"R139-20251030","doi-asserted-by":"crossref","first-page":"696961","DOI":"10.3389\/fphar.2021.696961","article-title":"Targeting fatty acid synthase modulates metabolic pathways and inhibits cholangiocarcinoma cell progression","volume":"12","author":"Tomacha","year":"2021","journal-title":"Front Pharmacol"},{"key":"R140-20251030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J Hepatol"},{"key":"R141-20251030","first-page":"5371","article-title":"Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2018","journal-title":"Exp Ther Med"},{"key":"R142-20251030","doi-asserted-by":"crossref","first-page":"23594","DOI":"10.18632\/oncotarget.4335","article-title":"Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"R143-20251030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3389\/fonc.2020.00694","article-title":"Targeting SphK2 reverses acquired resistance of regorafenib in hepatocellular carcinoma","volume":"10","author":"Shi","year":"2020","journal-title":"Front Oncol"},{"key":"R144-20251030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1078-0432.CCR-17-1707","article-title":"Global metabolic profiling identifies a pivotal role of proline and hydroxyproline metabolism in supporting hypoxic response in hepatocellular carcinoma","volume":"24","author":"Tang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R145-20251030","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2174\/156800911797264725","article-title":"L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells","volume":"11","author":"Tardito","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"R146-20251030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/hep.21531","article-title":"Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis","volume":"45","author":"Di Tommaso","year":"2007","journal-title":"Hepatology"},{"key":"R147-20251030","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1038\/emm.2017.174","article-title":"Glutamine synthetase mediates sorafenib sensitivity in beta-catenin-active hepatocellular carcinoma cells","volume":"50","author":"Sohn","year":"2018","journal-title":"Exp Mol Med"},{"key":"R148-20251030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2019.04.005","article-title":"GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT\/GSK3beta\/CyclinD1 pathway","volume":"381","author":"Xi","year":"2019","journal-title":"Exp Cell Res"},{"key":"R149-20251030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/bjc.2013.293","article-title":"Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma","volume":"109","author":"Zhang","year":"2013","journal-title":"Br J Cancer"},{"key":"R150-20251030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neo.2019.10.004","article-title":"Glutamine deprivation counteracts hypoxia-induced chemoresistance","volume":"22","author":"Wappler","year":"2020","journal-title":"Neoplasia"},{"key":"R151-20251030","doi-asserted-by":"crossref","first-page":"783194","DOI":"10.3389\/fonc.2021.783194","article-title":"A novel microcrystalline BAY-876 formulation achieves long-acting antitumor activity against aerobic glycolysis and proliferation of hepatocellular carcinoma","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"R152-20251030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41401-018-0014-x","article-title":"Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism","volume":"40","author":"Liu","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"R153-20251030","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1158\/0008-5472.CAN-21-0758","article-title":"Aspirin in hepatocellular carcinoma","volume":"81","author":"Ricciotti","year":"2021","journal-title":"Cancer Res"},{"key":"R154-20251030","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1940-6207.CAPR-15-0126","article-title":"NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project","volume":"8","author":"Petrick","year":"2015","journal-title":"Cancer Prev Res (Phila)"},{"key":"R155-20251030","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3892\/ol.2016.5510","article-title":"2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells","volume":"13","author":"Tomizawa","year":"2017","journal-title":"Oncol Lett"},{"key":"R156-20251030","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.2147\/OTT.S212465","article-title":"The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"R157-20251030","doi-asserted-by":"crossref","first-page":"13703","DOI":"10.18632\/oncotarget.3800","article-title":"By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice","volume":"6","author":"Dai","year":"2015","journal-title":"Oncotarget"},{"key":"R158-20251030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.trre.2015.02.003","article-title":"mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation?","volume":"29","author":"Duvoux","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"R159-20251030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bjc.2012.559","article-title":"Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma","volume":"108","author":"Shen","year":"2013","journal-title":"Br J Cancer"},{"key":"R160-20251030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.chembiol.2009.07.007","article-title":"A small molecule that blocks fat synthesis by inhibiting the activation of SREBP","volume":"16","author":"Kamisuki","year":"2009","journal-title":"Chem Biol"},{"key":"R161-20251030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41588-017-0027-2","article-title":"An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat Genet"},{"key":"R162-20251030","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1021\/jm200304y","article-title":"Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins","volume":"54","author":"Kamisuki","year":"2011","journal-title":"J Med Chem"},{"key":"R163-20251030","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-13-0382-T","article-title":"An essential requirement for the SCAP\/SREBP signaling axis to protect cancer cells from lipotoxicity","volume":"73","author":"Williams","year":"2013","journal-title":"Cancer Res"},{"key":"R164-20251030","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/hep.32359","article-title":"Therapeutic efficacy of FASN inhibition in preclinical models of HCC","volume":"76","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"R165-20251030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","article-title":"Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma","volume":"29","author":"Lally","year":"2019","journal-title":"Cell Metab"},{"key":"R166-20251030","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1158\/1535-7163.MCT-09-1064","article-title":"Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice","volume":"9","author":"Fritz","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"R167-20251030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lfs.2016.04.018","article-title":"Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells","volume":"153","author":"Buranrat","year":"2016","journal-title":"Life Sci"},{"key":"R168-20251030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1054\/bjoc.2000.1716","article-title":"Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial","volume":"84","author":"Kawata","year":"2001","journal-title":"Br J Cancer"},{"key":"R169-20251030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2019.04.021","article-title":"Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma","volume":"71","author":"Jouve","year":"2019","journal-title":"J Hepatol"},{"key":"R170-20251030","doi-asserted-by":"crossref","first-page":"e56749","DOI":"10.7554\/eLife.56749","article-title":"A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer","volume":"9","author":"Jin","year":"2020","journal-title":"Elife"},{"key":"R171-20251030","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/bjc.2014.425","article-title":"Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts","volume":"111","author":"Chiu","year":"2014","journal-title":"Br J Cancer"},{"key":"R172-20251030","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1158\/0008-5472.CAN-16-0787","article-title":"Body mass index, waist circumference, diabetes, and risk of liver cancer for US adults","volume":"76","author":"Campbell","year":"2016","journal-title":"Cancer Res"},{"key":"R173-20251030","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/COC.0000000000000388","article-title":"Obesity is independently associated with increased risk of hepatocellular cancer-related mortality: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"R174-20251030","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4103\/ijmr.IJMR_1910_18","article-title":"Subcutaneous adipose tissue & visceral adipose tissue","volume":"149","author":"Mittal","year":"2019","journal-title":"Indian J Med Res"},{"key":"R175-20251030","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2019.09.020","article-title":"Adipose tissue-associated cancer risk: is it the fat around the liver, or the fat inside the liver?","volume":"71","author":"Marchesini","year":"2019","journal-title":"J Hepatol"},{"key":"R176-20251030","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity\u2014a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"R177-20251030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","volume":"68","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"R178-20251030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.metabol.2016.01.010","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma","volume":"65","author":"Zoller","year":"2016","journal-title":"Metabolism"},{"key":"R179-20251030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mad.2016.07.001","article-title":"Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic steatohepatitis","volume":"157","author":"Bozaykut","year":"2016","journal-title":"Mech Ageing Dev"},{"key":"R180-20251030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1755-1536-1-5","article-title":"Redox mechanisms in hepatic chronic wound healing and fibrogenesis","volume":"1","author":"Novo","year":"2008","journal-title":"Fibrogenesis Tissue Repair"},{"key":"R181-20251030","doi-asserted-by":"crossref","first-page":"8543763","DOI":"10.1155\/2018\/8543763","article-title":"Molecular pathogenesis of nonalcoholic steatohepatitis- (NASH-) related hepatocellular carcinoma","volume":"2018","author":"Kutlu","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R182-20251030","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol Metab"},{"key":"R183-20251030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13046-019-1189-9","article-title":"Effects of short-term fasting on cancer treatment","volume":"38","author":"de Groot","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"R184-20251030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/tcm.10005","article-title":"Effects of fasting and intermittent fasting on rat hepatocarcinogenesis induced by diethylnitrosamine","volume":"22","author":"Rocha","year":"2002","journal-title":"Teratog Carcinog Mutagen"},{"key":"R185-20251030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/carcin\/18.1.159","article-title":"The effect of two periods of short-term fasting during the promotion stage of hepatocarcinogenesis in rats: the role of apoptosis and cell proliferation","volume":"18","author":"Hikita","year":"1997","journal-title":"Carcinogenesis"},{"key":"R186-20251030","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/carcin\/20.10.1979","article-title":"Effect of fasting\/refeeding on the incidence of chemically induced hepatocellular carcinoma in the rat","volume":"20","author":"Tomasi","year":"1999","journal-title":"Carcinogenesis"},{"key":"R187-20251030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/01635589809514716","article-title":"Hepatocellular carcinoma is induced by a subnecrogenic dose of diethylnitrosamine in previously fasted-refed rats","volume":"32","author":"Tessitore","year":"1998","journal-title":"Nutr Cancer"},{"key":"R188-20251030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"R189-20251030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd3504","article-title":"Targeting cancer metabolism: a therapeutic window opens","volume":"10","author":"Vander Heiden","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"R190-20251030","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/1878-0261.12666","article-title":"Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3\/FOXM1\/GLUT1 pathway","volume":"14","author":"Shang","year":"2020","journal-title":"Mol Oncol"},{"key":"R191-20251030","doi-asserted-by":"crossref","first-page":"5164100","DOI":"10.1155\/2021\/5164100","article-title":"Mechanism, clinical significance, and treatment strategy of Warburg effect in hepatocellular carcinoma","volume":"2021","author":"Chen","year":"2021","journal-title":"J Nanomater"},{"key":"R192-20251030","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/j.1742-4658.2012.08748.x","article-title":"Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma","volume":"279","author":"Sheng","year":"2012","journal-title":"FEBS J"},{"key":"R193-20251030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00432-014-1888-8","article-title":"Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration","volume":"141","author":"Gao","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"R194-20251030","doi-asserted-by":"crossref","first-page":"e93256","DOI":"10.1371\/journal.pone.0093256","article-title":"AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS One"},{"key":"R195-20251030","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/s41598-019-39556-w","article-title":"Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration","volume":"9","author":"Ferretti","year":"2019","journal-title":"Sci Rep"},{"key":"R196-20251030","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.7314\/APJCP.2015.16.18.8079","article-title":"Benefits of metformin use for cholangiocarcinoma","volume":"16","author":"Kaewpitoon","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"R197-20251030","doi-asserted-by":"crossref","first-page":"e014961","DOI":"10.1136\/bmjopen-2016-014961","article-title":"Study protocol of a phase IB\/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours","volume":"7","author":"Molenaar","year":"2017","journal-title":"BMJ Open"},{"key":"R198-20251030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/15384101.2017.1282586","article-title":"Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma","volume":"16","author":"Che","year":"2017","journal-title":"Cell Cycle"},{"key":"R199-20251030","doi-asserted-by":"crossref","first-page":"14689","DOI":"10.1038\/ncomms14689","article-title":"Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival","volume":"8","author":"Nelson","year":"2017","journal-title":"Nat Commun"},{"key":"R200-20251030","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1158\/1078-0432.CCR-12-3249","article-title":"Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma","volume":"19","author":"von Roemeling","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R201-20251030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bmcl.2009.11.111","article-title":"Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)","volume":"20","author":"Leger","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"R202-20251030","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1038\/onc.2017.75","article-title":"Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP\/TAZ","volume":"36","author":"Noto","year":"2017","journal-title":"Oncogene"},{"key":"R203-20251030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.stem.2016.11.004","article-title":"Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells","volume":"20","author":"Li","year":"2017","journal-title":"Cell Stem Cell"},{"key":"R204-20251030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000156702","article-title":"Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma","volume":"78","author":"Graf","year":"2008","journal-title":"Digestion"},{"key":"R205-20251030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.109.163444","article-title":"Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2","volume":"333","author":"French","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R206-20251030","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-16-2363","article-title":"A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors","volume":"23","author":"Britten","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R207-20251030","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.cellsig.2014.04.002","article-title":"Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration","volume":"26","author":"Janpipatkul","year":"2014","journal-title":"Cell Signal"},{"key":"R208-20251030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/msb.2010.62","article-title":"HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology","volume":"6","author":"Gille","year":"2010","journal-title":"Mol Syst Biol"},{"key":"R209-20251030","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1038\/ncomms4083","article-title":"Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease","volume":"5","author":"Mardinoglu","year":"2014","journal-title":"Nat Commun"},{"key":"R210-20251030","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/msb.145122","article-title":"Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling","volume":"10","author":"Agren","year":"2014","journal-title":"Mol Syst Biol"},{"key":"R211-20251030","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fphys.2018.00916","article-title":"Metabolic network-based identification and prioritization of anticancer targets based on expression data in hepatocellular carcinoma","volume":"9","author":"Bidkhori","year":"2018","journal-title":"Front Physiol"},{"key":"R212-20251030","doi-asserted-by":"crossref","first-page":"E11874","DOI":"10.1073\/pnas.1807305115","article-title":"Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes","volume":"115","author":"Bidkhori","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R213-20251030","doi-asserted-by":"crossref","first-page":"45557","DOI":"10.1038\/srep45557","article-title":"Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133","volume":"7","author":"Hur","year":"2017","journal-title":"Sci Rep"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:16Z","timestamp":1761807676000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":213,"URL":"https:\/\/doi.org\/10.1097\/hep.0000000000000005","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"2022-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}